Histologic Assessment in Wilms Tumor After Nephrectomy
The pathologist must assess for anaplasia (focal vs. diffuse) as the single most critical histologic feature, as this distinction fundamentally determines whether the patient receives standard chemotherapy (DD4A for focal anaplasia) or intensified regimens (revised UH-1 or UH-2 for diffuse anaplasia), along with mandatory radiation therapy. 1
Key Histologic Features to Assess
Primary Classification: Anaplasia Status
The pathologist must definitively categorize the tumor as:
- Favorable histology Wilms tumor (FHWT) - no anaplasia present
- Focal anaplastic Wilms tumor (FAWT) - anaplasia confined to discrete areas
- Diffuse anaplastic Wilms tumor (DAWT) - anaplasia present throughout the tumor
Critical caveat: Anaplasia identified on biopsy alone is automatically considered diffuse, as sampling cannot rule out more widespread disease 1. This is why core needle biopsy failed to identify anaplasia in 7 of 7 cases in one study, while open biopsy or resection identified it in 10 of 18 cases 2.
Secondary Features in Favorable Histology
For FHWT (after neoadjuvant chemotherapy), assess:
- Blastemal predominance - requires intensified therapy (Regimen I) due to higher relapse risk 1
- Stromal or epithelial predominance - indicates differentiated tumor with better prognosis
- Degree of necrosis - complete necrosis (17% of cases post-chemotherapy) vs. viable tumor 3
Treatment Algorithm Based on Histology
Favorable Histology (No Anaplasia)
Stage I-III:
- Standard chemotherapy (typically DD4A or EE4A depending on stage)
- Radiation only for Stage III disease (flank or whole abdomen)
Blastemal-predominant FHWT:
- Requires augmented therapy with Regimen I regardless of stage 1
- Higher risk of relapse necessitates intensification
Focal Anaplasia
Stage I-III:
- Switch to Regimen DD4A 1
- Flank radiation for Stage I-II
- Flank or whole abdomen radiation for Stage III
- Important: Stage III FAWT may warrant intensification based on inferior outcomes in AREN0321 study 1
Stage IV:
- Switch to revised Regimen UH-1 (more intensive) 1
- Flank radiation for local Stage I-II
- Flank or whole abdomen for local Stage III
- Whole lung irradiation for pulmonary metastases
Diffuse Anaplasia
Stage I:
- Switch to Regimen DD4A 1
- Mandatory flank radiation
Stage II-IV:
- Switch to revised Regimen UH-2 (most intensive regimen) 1
- Flank radiation for local Stage II
- Flank or whole abdomen for local Stage III
- Higher radiation dose for Stage III DAWT - proven to reduce local recurrence risk 1
- Whole lung irradiation for pulmonary metastases
Radiation Therapy Timing
Radiation must begin within 10-14 days after surgery 1. Planning should anticipate potential overlapping fields if both abdominal and lung radiation are needed, even if lung radiation is not ultimately given, to minimize overlap complications 1.
Critical Pitfalls to Avoid
Inadequate tissue sampling: Core needle biopsy has 0% sensitivity for detecting anaplasia 2. Open biopsy or resection is required for accurate diagnosis.
Bilateral disease discordance: In bilateral Wilms tumor, 20 of 24 patients had discordant pathology between kidneys 2. Each kidney must be assessed independently.
Post-chemotherapy changes: Neoadjuvant chemotherapy dramatically alters histology - blastema decreases from 89% to 50% of tumors, with 17% becoming completely necrotic 4. The pathologist must account for treatment effect when assessing viable tumor components.
Misclassifying focal vs. diffuse anaplasia: This distinction has profound prognostic implications - focal anaplasia has significantly better outcomes than diffuse 1, 5. The 1996 updated definitions must be applied rigorously.
Delayed diagnosis of anaplasia: Mean duration on inappropriate chemotherapy was 20-39 weeks when anaplasia was missed on initial biopsy 2. Early adequate tissue sampling is essential.